Paradromics, a neurotech startup based in Austin, Texas, is gearing up to conduct clinical trials of its brain implant technology next year, marking a significant step forward in the competitive field of brain-computer interfaces (BCIs). Matt Angle, CEO and founder of Paradromics, emphasized the complexity and potential of the human brain, which boasts 85 billion… Continue reading Neuralink competitor Paradromics gears up to test its brain implant on humans

Merck has achieved a significant milestone with the FDA approval of Capvaxive, a novel pneumococcal conjugate vaccine designed specifically for adults. This vaccine targets 21 strains of pneumococcus bacteria, offering broader protection than existing shots and aiming to prevent severe forms of pneumococcal disease, including pneumonia. The approval marks the first of its kind tailored… Continue reading FDA approves Merck vaccine designed to protect adults from bacteria that can cause pneumonia, serious infections

U.S. employers are increasingly covering GLP-1 drugs for weight loss, with about one-third of employer health plans now including these medications, up from 26% last year. GLP-1 drugs, like Novo Nordisk’s Ozempic and Wegovy, have grown in popularity due to their effectiveness in weight loss and diabetes management. As a result, these drugs now account… Continue reading Healthy Returns: More U.S. employers are now covering GLP-1s for weight loss

Unidoc Health Corp. has received an inaugural purchase order from HP Inc. for 10 AI-equipped H3 Health Cubes. The order includes six indoor and four outdoor-rated cubes, equipped with eHealth instruments and NEIL Connect(TM) AI software. Key Features: UniDoc receives order from HP for ten (10) AI-equipped H3 Health Cubes Includes six indoor and four… Continue reading UNIDOC RECEIVES PURCHASE ORDER FROM HP INC. FOR 10 AI-EQUIPPED H3 HEALTH CUBES

Over the past year, Eli Lilly has experienced significant growth due to skyrocketing demand for its weight loss and diabetes treatments, particularly Mounjaro and the recently launched Zepbound. Outgoing Chief Financial Officer Anat Ashkenazi, who will become the new CFO of Alphabet on July 31, has been instrumental in managing the revenue surge and investor… Continue reading How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi

In a significant decision, the Supreme Court ruled against a challenge to the accessibility of the abortion pill mifepristone, maintaining its widespread availability. The court unanimously determined that the group of anti-abortion doctors lacked legal standing to sue over the Food and Drug Administration’s (FDA) easing of restrictions on the drug. Justice Brett Kavanaugh, writing… Continue reading Supreme Court rejects bid to restrict access to abortion pill

The Vitamin Shoppe’s 2024 Health & Wellness Trend Report reveals a growing consumer interest in protein supplements, driven by the weight loss boom and the use of GLP-1 medications. This annual study, surveying 2,000 Americans, highlights key trends in the nutritional supplements industry, showing that as more people use weight loss treatments like GLP-1 drugs,… Continue reading Weight loss boom is spurring sales of protein, meal replacement products, Vitamin Shoppe CEO says

TORONTO, June 12, 2024 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today an update on the Type C meeting written responses received by… Continue reading Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID

Vancouver, British Columbia–(Newsfile Corp. – June 11, 2024) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company“), a leading Health Canada licensed GMP psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to announce a series of milestones in its international psychedelic supply operations… Continue reading Optimi Health Completes First International Shipment of MDMA to Israel and Secures CBSA Exporters Authorization ID

Toronto, Ontario – TheNewswire – June 11, 2024 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company“), (TSXV:VPT; OTC:VPTDF) announced a teleconference to be conducted June 14th at which an update to shareholders will be provided. “During the first quarter we focused on effecting leadership change in the company and assessing the status of the technology,… Continue reading Ventripoint Diagnostics Announces Shareholder Update and Teleconference

Moderna announced that its combination vaccine targeting both Covid-19 and the flu proved more effective than existing standalone shots in a late-stage trial. This marks the first instance of positive phase three data for a Covid and flu combination shot, potentially giving Moderna an edge over rivals Pfizer and Novavax. Moderna plans to seek regulatory… Continue reading Moderna’s combination Covid, flu vaccine is more effective than existing shots in late-stage trial

TORONTO, June 10, 2024 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today an update on the meeting written responses received by the Company… Continue reading Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product